This is a corrigendum to:
Sabine Mueller, Jason Fangusaro, Arzu Onar Thomas, Thomas S Jacques, Pratiti Bandopadhayay, Peter de Blank, Roger J Packer, Maryam Fouladi, Antoinette Schouten van Meeteren, David Jones, Arie Perry, Yoshiko Nakano, Darren Hargrave, David Riedl, Nathan J Robinson, Marita Partanen, Michael J Fisher, Olaf Witt, Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group, Neuro-Oncology, 2023;, noad227, https://doi.org/10.1093/neuonc/noad227
In the originally published version of this manuscript, “Tovorafenib” is misspelled as “tovarafenib” in 2 places on page 3 and Reference 65 should be:
Kilburn, L.B., Khuong-Quang, DA., Hansford, J.R. et al. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med (2023). https://doi.org/10.1038/s41591-023-02668-y
This error has been corrected.